, which is conserved in the Cip/Kip proteins, is implicated in protein-protein interaction and confers a specific regulatory mechanism, outside of their Cdk-inhibitory activity, by which the p57 Kip2 family members positively act on myogenic differentiation.
1 that regulate pRB and its related proteins through phosphorylation. Cyclin-dependent kinases are themselves regulated by a number of regulators including the cyclin-dependent kinase inhibitors (Ckis) (2) . Ckis induce cell cycle arrest in response to anti-proliferative signals, including contact inhibition and serum deprivation (3), transforming growth factor-␤ (4) and myogenic (5) , myeloid (6) , and neuronal differentiation (7) . Ckis can be divided in two families (2, 8) . The Ink4 family includes p16
Ink4a , p15 Ink4b , and p18 Ink4c , which specifically bind and inhibit Cdk4 and Cdk6; and p19
ARF , which has a tumor suppression function dependent upon the p53 (9) . p21
Cip1 , p27 Kip1 , and p57 Kip2 , members of the other family of inhibitors, the Cip/Kip family, have the ability to inhibit all G 1 /S phase Cdks complexes (10 -12) . Although p21
Cip1 expression during development correlates with terminally differentiating tissues, mice lacking p21
Cip1 have normal development (13) . p27 Kip1 -deficient mice have a grossly normal development but display several phenotypes that seem to be linked to cell proliferation (14 -16) . p57
Kip2 is also a tightly binding inhibitor of cyclin D-Cdk4-Cdk6 complexes and a negative regulator of cell proliferation (17, 18) . The expression pattern of p57 mRNA in various adult human tissues suggests that its distribution is more restricted than that of p21
Cip1 and p27 Kip1 (17, 18) . The p57
Kip2 gene is located in 11p15.5, a region suggested to be involved in sporadic cancers and the Beckwith-Wiedmann syndrome (17) . Specific loss of the maternal allele has been observed in several types of childhood tumors including Wilm's tumors and rhabdomyosarcoma, suggesting a genomic imprinting, which has been confirmed both in mice and human. Generation of null mice for p57 Kip2 has revealed a phenotype close to the syndrome observed in human. Mice died upon birth and showed macroglossia, omphalocele, gigantism, various levels of limb shortening, and an important modification in the skeletal muscle distribution, suggesting that p57
Kip2 has an important role during development (19, 20) . The lack of p21
Cip1 or p27 Kip1 functions does not lead to gross developmental defects, suggesting the existence of compensatory mechanisms during development. Such a redundant mechanism has been recently shown; mice lacking both p21 Cip1 and p57 Kip2 display severe defects in skeletal muscle development (and other tissues including lung). These two Ckis cooperate as terminal effectors of signaling pathways that impinge on cell cycle control and differentiation and control muscle differentiation at the myogenin step (21) .
To undergo differentiation, myogenic cells have to exit the cell cycle through the G 1 checkpoint. Myogenic differentiation is under the control of a family of muscle-specific transcription factors (MRFs), which includes MyoD (22) , myogenin (23, 24) , Myf5 (25) , and MRF4 (26) , also known as herculin (27) or Myf6 (28) . These proteins share a central basic helix-loop-helix (bHLH) domain that is involved in DNA binding and proteinprotein interactions (29) . This 70-amino acid region accounts for their ability to form heterodimers with the E protein bHLH factors (30, 31) , to bind as heterodimers to an E-box DNA consensus sequence (CANNTG) (29) , to transactivate muscle genes, and to efficiently convert non-muscle cells to a myogenic lineage (32) . MyoD is expressed in proliferating myoblasts prior to terminal differentiation (33) . A number of molecular mechanisms have been proposed to explain the functional inactivation of MyoD in proliferating myoblasts and the coupling of muscle differentiation with the cell cycle arrest (34) . These include inhibitory phosphorylation of the myogenic bHLH proteins (35) (36) (37) , inhibition of the myogenic bHLH function via the Id family of dominant-negative helix-loop-helix factors (38) , and either direct or indirect inhibition by the cyclin D-dependent kinases (39, 40) . It has been previously shown that overexpression of cyclin D-Cdk complexes inhibited myogenic transcriptional activation mediated by MyoD (41) and that cell cycle arrest correlates with the induction of p21 Cip1 by MyoD (42, 43) . The role of Cdks in inhibiting muscle differentiation has been substantiated by the observation that forced expression of p21
Cip1 and/or p16 Ink4a in mitogen-stimulated myoblasts facilitates muscle differentiation in the absence of mitogen deprivation suggesting that an active cyclin-Cdk complex suppresses MyoD function in proliferating myoblasts (40) . It has been recently proposed that Cdk phosphorylation of MyoD can target this protein for rapid degradation (44) . Indeed, recent data show that direct phosphorylation of MyoD Ser200 by Cdk1 or Cdk2 plays a crucial role in modulating MyoD half-life and myogenic activity (45) . In contrast to Cdk1 and Cdk2, cyclin D1-Cdk4 complexes fail to phosphorylate MyoD (46) . The cyclin-Cdk-mediated inhibition of myogenesis by cyclin D1 involves nuclear translocation of Cdk4 by cyclin D1 and the subsequent formation of a MyoD-Cdk4 complex that specifically inhibits the transactivation functions of MyoD in absence of Cdk4 kinase activity (46) . Interestingly, degradation of MyoD by the ubiquitin-proteasome pathway is inhibited by the specific DNA sequence to which MyoD binds independently of its phosphorylation state. Formation of a proteolysis-resistant complex seems to be dependent on dimerization and DNA binding of MyoD proteins (47) .
Here we show that half-life of MyoD Ala200 , which is not phosphorylatable in vivo by the cyclin-Cdk complexes, is augmented in the presence of p57 Kip2 , suggesting that a mechanism distinct from phosphorylation-dependent degradation stabilizes MyoD. We show that MyoD but not its partner E12 physically interacts with p57 Kip2 . Mutational and functional analyses of the two proteins demonstrate that the NH 2 domain of p57
Kip2 associates with the basic domain of MyoD. Moreover, competition/association and site-directed mutagenesis of the NH 2 -terminal domain of p57
Kip2 define the intermediate ␣-helix structure, located between the cyclin and the Cdk binding sites, as the important structural element involved in this interaction. These results strongly suggest that p57
Kip2 may function in myogenic differentiation via two distinct mechanisms; one is an inhibitor of active cyclin-Cdk complexes, which control the G 1 phase of cell cycle and the phosphorylationdependent degradation of MyoD (48) , and the second mechanism, via a physical interaction, stabilizes MyoD independently of its phosphorylation state during the course of myogenic differentiation.
EXPERIMENTAL PROCEDURES
Plasmids-pEMSV-MyoD, pEMSV-MyoD mutants, and pEMSV-E12 were generous gifts from the Weintraub laboratory. pEMSV-MyoD Ala200 mutant was obtained from M. Kitzmann (45) . Expression vectors pCMV-HA-MyoD was generated by cloning three hemagglutinin epitope tags (3Tag HA) at the amino terminus of cDNA insert in pcDNA3 (Invitrogen). The reporter plasmid MCK-Luc (p1256MCK), generously provided by S. Hauschka, contains the promoter-enhancer region from the mouse muscle creatine kinase. pEX10X-p57
Kip2 was kindly supplied by J. Massagué. CMV-p16
Ink4a was a kind gift from B. Heinglein. Cyclin D1 and Cdk4 were kindly supplied by C. Sherr. To create expression vectors, fragments containing the complete coding sequences were cloned into pcDNA3 expression vectors (Invitrogen) and/or in pEMSV scribe.
Expression vectors pCMV-HA-p57
Kip2
, pCMV-HA-Cdk4, and pCMV-HA-cyclin D1 were generated by cloning three hemagglutinin epitope tags (3Tag HA) at the amino terminus of cDNA inserts in pcDNA3.
pGEX-2TK-p57 Kip2 was obtained by inserting in frame the NcoIHindIII fragment from pEX10X-57 Kip2 , into the NcoI-HindIII sites of plasmid pGEX-2TK expression plasmid (Amersham Pharmacia Biotech). pGEX-2T-p57⌬CKI was constructed by inserting in frame the SmaI-PvuII fragment from pGEX-2TK-p57 Kip2 , at the SmaI site of pGEX-2T expression plasmid. pGEX-2TK-p57⌬CKI was constructed by deleting a NcoI-BglII fragment, of the pGEX-2TK-p57
. pGEX-3X-p57⌬PAC was obtained by deleting the PvuII-SmaI fragment of pEX10X-p57 Kip2 , the plasmid at this stage was closed, amplified, and used to generate a deleted p57-containing fragment NcoI-HindIII inserted in-frame into pGEX-2TK expression vector. pGEX-3X-p57PAC was obtained by inserting in-frame the PvuII-SmaI fragment, obtained from pGEX-2TK-p57 Kip2 , at the SmaI-filled site of pGEX-3X. pGEX-2TK-p57⌬QT was generated by inserting in-frame the BlpI-filled-in HindIII fragment, obtained from pEX10X-p57 Kip2 , at the SmaI site of pGEX-2TK. pGEX-2TK-p57QT was generated by inserting in frame the SmaI fragment, obtained from pGEX-2TK-p57 Kip2 , at the SmaI site of pGEX-2TK. p57
Kip2 mutant R33L was generated by polymerase chain reaction with a 5Ј primer (5Ј-GAGCTGGGCCTCGAGCTGCGGATGC-3Ј) and a 3Ј primer (3Ј-GCATCCGCAGCTCGAGGCCCAGCTC-3Ј) using pEMSV-scribe p57
Kip2 wild type as template and the QuickChange TM site-directed mutagenesis kit (Stratagene, Ozyme) as instructed by the manufacturer. The Rsa mutated insert was then subcloned in-frame in pGEX-3X expression plasmid at the EcoRI site filled in by the Klenow polymerase to create pGEX-p57R33L.
Cell Cultures, DNA Transfection, and Luciferase Assays-The mouse skeletal muscle cell line C2C12 and the fibroblastic cell line C3H10T1/2 were maintained in growth medium supplemented with antibiotics (a mixture of penicillin and streptomycin (Life Technologies, Inc.) and with 20% and 15% of fetal calf serum in Dulbecco's modified Eagle's medium, respectively. C2C12 cells were transfected by the calcium phosphate procedure as described previously (49) . C3H10T1/2 fibroblasts were transfected by using polyethylenimine essentially as described (50) . Briefly, 3 ϫ 10 4 cells/well were plated onto 24-well plates. On the following day, cells were transfected with various combinations of plasmids, as indicated in legends of the figures. The total amount of DNA used for each plate was normalized with the respective empty expression vector. Luciferase activity was determined in aliquots of cell extracts from harvested cells 48 h after transfection in growth medium. One hundred nanograms of the pEGFP-C1 plasmid (Invitrogen) was included in transfections as an internal control for transfection efficiency. All luciferase activities were determined with equivalent quantities of proteins in triplicate and repeated at least twice.
Cycloheximide Treatment-C3H10T1/2 cells were transfected with either pCDNA3-HA-MyoD or pCDNA3-HA-MyoD Ala200 alone or with pEMSV-p57
Kip2 in six-well plates as described above. Transfected cells were treated with cycloheximide (Sigma) at 15 g/ml for the indicated times and harvested for Western blot analyses. HA-MyoD and HAMyoD Ala200 were detected using anti-HA antibodies (12CA5, Roche Molecular Biochemicals). For each experiment, ␣-tubulin was used as an internal control. Western blots were scanned and quantified by using a GelScan (Amersham Pharmacia Biotech).
Protein Expression, Purification, and GST Pull-down Assay-Bacterial expression of proteins was performed in Escherichia coli BL21. Protein induction, cell lysis, and affinity purification with glutathioneagarose beads (Sigma) were done as described previously (51) . In brief, GST-MyoD and GST-p57
Kip2 fusion proteins were prepared and the fusion proteins were not eluted but washed four times at 4°C in NTEN buffer (20 mM Tris, pH 8, 100 mM NaCl, 1 mM EDTA, 0, 5% Nonidet P-40) containing protease inhibitors and phosphatase inhibitors. Fu-sion proteins were collected on glutathione-Sepharose 4B (Amersham Pharmacia Biotech), and then the purity of the GST and GST fusion proteins were analyzed by SDS-PAGE and estimated to be 70 -80% of purity by Coomassie Brillant Blue staining of the gels. 35 S-Labeled proteins were prepared by coupled in vitro transcription-translation using the TnT-coupled rabbit reticulocyte lysate system (Promega). GST pull-down assays were performed as described previously (51) . The programmed lysates (1-10 l) were incubated with GST alone and GST fusion proteins overnight at 4°C. Beads were washed four times in NTEN buffer at room temperature and then mixed with one volume of 2ϫ SDS loading buffer, and bound proteins were analyzed by SDS-PAGE by using standard procedures.
For the competition/association assays, GST-p57 Kip2 -covered beads were first incubated with 35 S-labeled in vitro translated MyoD for 2 h at 4°C. Then, unbound 35 S-labeled MyoD protein was removed by three wash cycles of binding buffer. Increasing amounts of labeled cyclin D1, Cdk4, or cotranslated cyclin D1-Cdk4 complexes were then added to the binding reactions, and the resulting mixtures were subjected to a GST pull-down assay. The reaction products were separated on SDS-PAGE. Bound proteins were detected by autoradiofluorography and quantified by using PhosphorImager.
Antibodies, Immunoprecipitation, and Western Blot AnalysesWhole cell extracts from cultured cells were prepared in ice-cold radioimmune precipitation EGTA buffer (50 mM Hepes, pH 7.6, 150 mM NaCl, 2.5 mM EGTA, 1 mM EDTA, 10 M ␤-glycerophosphate, 0.1 mM sodium orthovanadate, 1 mM NaF, 0.1% Tween 20, 10% glycerol, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml leupeptin, 1 g/ml aprotinin, and 1 g/ml pepstatin). Lysates were centrifuged at 4°C for 10 min in a microcentrifuge set at maximum speed, and the supernatant was stored at Ϫ80°C in small aliquots. For immunoprecipitation, precleared cell lysates in immunoprecipitation buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol, 0.5% Nonidet P-40, 0.5 mM sodium orthovanadate, 50 mM NaF, 80 M ␤-glycerophosphate, 10 mM sodium pyrophosphate, 1 mM dithiothreitol, 1 mM EGTA, 10 g/ml leupeptin, 10 g/ml pepstatin, and 10 g/ml aprotinin) were incubated with the indicated antibodies for 2-3 h at 4°C with gentle agitation. Immunocomplexes bound to protein G-Sepharose were collected by centrifugation and washed several times in immunoprecipitation buffer. Immunoprecipitated proteins were resolved by 10% SDS-PAGE, followed by autoradiofluorography ( 35 S-labeled proteins) and/or autoradiography.
For immunoblot analysis, total cell extracts or immunoprecipitates were solubilized in radioimmune precipitation EGTA buffer and processed as described previously (52) . Analyses were performed on 10% polyacrylamide gels with a 5% polyacrylamide stacking gel. Electrophoretic transfer of proteins from SDS-PAGE gels to nitrocellulose membranes were blocked with 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.05% Tween 20 containing 5% skim milk and incubated overnight at 4°C with primary antibodies: polyclonal C20 anti-MyoD diluted 1/500, polyclonal E-17 anti-mouse p57
Kip2 diluted 1/250, polyclonal C-22 anti-Cdk4 diluted 1/1000, and polyclonal M-156 anti-p16 diluted 1/250 were provided by Santa Cruz Biotechnology (Santa Cruz, CA). The monoclonal 12CA5 anti-HA antibody was provided by Roche Molecular Biochemicals. Monoclonal anti-myosin light chain 1 clone MY-21 diluted 1/200, monoclonal anti-myosin heavy chain clone MY-32 diluted 1/400, and anti-␣-tubulin clone DM1A diluted 1/500 were supplied by Sigma. Membranes were washed and incubated 1 h with a peroxidaseconjugated secondary antibody (Sigma) at a dilution of 1/10,000 with polyclonal antibodies and 1/4,000 with monoclonal antibodies. After several washes, membranes were incubated with an enhanced chemiluminescence system (ECL, Amersham Pharmacia Biotech) according to the manufacturer's instructions. Exposure was done with Agfa Curix RP2 films and intensifying screens.
RESULTS

p57
Kip2 Increases Muscle-specific Gene Transactivation by MyoD Ala200 -Phosphorylation of MyoD is one of the crucial mechanisms that control its activity in eukaryotic cells, and recent reports show that in proliferating myoblasts phosphorylation of MyoD at serine 200 (44) by Cdk1 or Cdk2 (45) appears to play a major role in modulating MyoD half-life and myogenic activity. We have recently shown that p57
Kip2 can stabilize MyoD protein by inhibiting cyclin E-Cdk2 kinase activity in growing myoblasts (48) . Transient transfection assays were performed to compare the effects of p57
Kip2 on MyoD wild type (MyoD wt ) and MyoD Ala200 -mediated expression of muscle specific genes. C3H10T1/2 cells were transiently transfected with expression vectors encoding p57
Kip2 and/or MyoD wt and MyoD Ala200 along with a skeletal muscle reporter construct containing 1256 base pairs from the muscle creatine kinase promoter driving expression of luciferase (MCK-Luc). MCKLuc was not expressed in C3H10T1/2 cells when transfected alone, but it was efficiently activated by cotransfection with a MyoD wt or MyoD Ala200 expression vectors (Fig. 1, lanes 1-3) .
Co-expression of p57
Kip2 not only increased the transactivation of MCK-Luc by MyoD wt but also by MyoD Ala200 in a dose-dependent manner. In our experiments, we observed, respectively, a 15-and 6-fold increase in the level of Luc expression driven by the MCK-Luc construct in the presence of p57 Kip2 ( Fig. 1, lanes 5 and 6) . The control plasmid MCK-Luc alone Kip2 alone (lanes 4) or 1.5 g in combination (lanes 5 and 6). pEMSV expression vector without insert were included to normalize DNA in all transfections. Luciferase levels were determined 48 h after transfections in high serum medium (15% fetal calf serum). Protein concentrations were equalized by Bradford assay. B, C3H10T1/2 cells were transfected with pcDNA-HA-MyoD Ala200 alone (lanes 1 and 3) or in combination with pEMSV-p57 Kip2 (lanes 2 and 4) as described above. Transfected cells were grown in proliferative medium (Dulbecco's modified Eagle's medium containing 15% fetal calf serum) for 48 h (P) and placed in differentiation medium for 48 h (48 h). Cells were collected either before (P) or after (48 h) myogenic conversion and analyzed by Western blotting for MyoD, p57 Kip2 , myosin heavy chain (MHC), myosin light chain 1 (LC1), and Cdk4 expression.
( Fig. 1, lane 1) or p57
Kip2 alone were inactive on MCK activity (Fig. 1, lane 4) . During the course of differentiation, other muscle specific proteins were likewise up-regulated in cells cotransfected with p57
Kip2 and MyoD Ala200 compared with the transfection of MyoD Ala200 alone. These include myosin heavy chain and myosin light chain 1 and, surprisingly, MyoD Ala200 (Fig. 1B) Ink4a on the level of co-expressed MyoD Ala200 in C3H10T1/2 fibroblasts in transient transfectants. As previously observed (Fig. 1B) , immunoblotting analyses confirmed that p57 Kip2 increased the level of co-expressed MyoD Ala200 ( Fig. 2A, lanes 2  and 3) in a dose-dependent manner while co-expression of empty vector or p16
Ink4a did not affect the expression level of MyoD Ala200 ( Fig. 2A, lanes 4 -7) . Our data show that Myo-D Ala200 expression is specifically augmented in presence of the p57 Kip2 proteins. Because MyoD Ala200 is nonphosphorylatable by cyclin-Cdk complexes and is much more stable than MyoD wt (45) , the stability of MyoD Ala200 compared with MyoD wt in the presence of p57
Kip2 was also investigated. We transfected MyoD wt and MyoD Ala200 in C3H10T1/2 cells and determined their half-life following cycloheximide treatment (Fig. 2B) . We previously showed that the half-life of MyoD wt was found to be about 50 min, in agreement with previous reports (45, 53, 54) and as recently reported, MyoD Ala200 has a half-life 5-fold higher than MyoD wt (44, 45) . In the presence of p57 Kip2 , the half-life of MyoD wt was extended to 3 h (48). In the same conditions, the half-life of MyoD Ala200 was extended over 10 h (Fig. 2, B and C) . Expression level of ␣-tubulin, a stable protein, was not modified until 8 h after cycloheximide addition. These results strongly suggest that p57 Kip2 stabilizes MyoD Ala200 by a biochemical mechanism that is independent of MyoD phosphorylation by Cdks.
In Vivo Detection of p57 Kip2 -MyoD Complexes-Recently, degradation of MyoD by the ubiquitin-proteasome pathway has been shown to be regulated by specific DNA binding involving homodimerization or formation of E47-MyoD heterodimers in vitro and in vivo independently of the phosphorylation of MyoD (47) . These data suggest that specific binding of MyoD prevents its degradation and causes the accumulation of MyoD in cultured cells. One possibility involved in the stabilization of MyoD could be its interaction with p57
Kip2 . To test this hypothesis, C3H10T1/2 cells were transiently transfected with pCMV-HA-MyoD and pCMV-HA-p57
Kip2 alone and/or in combination and total cellular proteins were immunoprecipitated with antiMyoD antibodies. The immune complexes were then analyzed by Western blotting using the anti-HA monoclonal antibodies. p57
Kip2 was only immunoprecipitated with anti-MyoD antibodies in cells cotransfected with pCMV-HA-MyoD and pCMV-HAp57 Kip2 (Fig. 3, A where anti-p57 Kip2 antibodies were used for the immunoprecipitation (Fig. 3C, lanes 3 and 4) . The coimmunoprecipitation of MyoD-p57
Kip2 was specific because it was not observed with anti-p16 antibodies (Fig. 3C, lanes 1 and 2) . We have recently shown that p57 Kip2 and MyoD are up-regulated in the course of muscle differentiation (48) . Indeed, in differentiating C2C12 myotubes, higher levels of associated p57 Kip2 and MyoD proteins were observed than in proliferating C2C12 myoblasts (Fig. 3C, lanes 3 and 4) . Altogether, our results show that p57
Kip2 can bind to MyoD in vivo.
MyoD but Not E12 Binds to p57 Kip2 -To determine if the interaction observed between MyoD and p57
Kip2 is direct or mediated by a third partner, a biochemical approach was used.
GST or GST-p57
Kip2 -covered beads were incubated with 35 Slabeled in vitro translated MyoD, E12, or cyclin D1 (used as positive control). MyoD could bind efficiently to the p57 Kip2 protein, while no binding was observed with E12 ( Fig. 4A) and/or MyoD-E12 heterodimers (data not shown). To ensure that the direct binding of MyoD with the p57
Kip2 protein was not mediated through a particular conformation of GSTp57
Kip2 fusion protein, the converse experiments, in which beads were coated with MyoD and incubated with 35 S-labeled in vitro translated p57
Kip2 or p16 Ink4a , were undertaken. E12 was used as a positive control. Data shown in Fig. 4B confirmed that p57
Kip2 bound significantly to GST-MyoD. Altogether, these data show that in vitro p57
Kip2 but not p16 Ink4a is able to bind with MyoD.
Mapping the Binding Domains of MyoD and p57
Kip2 -The domains of each polypeptide required for this interaction were mapped by in vitro protein binding experiments (Figs. 5 and 6 ). Full-length in vitro translated MyoD efficiently bound to GSTp57
Kip2 but not to GST alone (Fig. 4A and 5) . Removing amino acids 63-99 from the NH 2 terminus or amino acids 218 -269 from the COOH terminus of MyoD did not affect the interaction with GST-p57 Kip2 (Fig. 5, B and C, lanes 2 and 5) . In contrast, MyoD mutants in which the basic region (DM: 102-114), or the basic region and the helix 1 (DM: 102-135), or the mutants MyoD E12 basic and or MyoD T4 basic (mutants of MyoD in which the basic domain has been replaced by the E12 basic and/or the T4 basic domain, respectively) did not bind to GSTp57 Kip2 beads (Fig. 5, B and C, lanes 3 and 4 and lanes 6 and 7) . These data indicate that the basic domain of MyoD mediates its binding to p57 Kip2 . To determine the domain of p57
Kip2 involved in the binding to MyoD, various Kip2 fusion proteins containing either the wild type p57
Kip2 protein (wt), the complete Cdk inhibition domain (Cki), the prolin-rich and acidic repeat domains (PAC), the QT domain (QT) or the wild type p57
Kip2 deleted of the Cdk inhibitor domain (⌬CKI), deleted of the QT domain (⌬QT) or deleted of the prolin-rich plus acidic repeat domains (⌬PAC) were tested for binding to in vitro translated MyoD (Fig. 6) . Cyclin D1 was used as a positive control. The results are shown in Fig. 6 (A and B) and summarized in Fig. 6C . They show that the NH 2 domain, which contains the cyclin-Cdk binding sites, is necessary and sufficient for p57
Kip2 binding to MyoD.
Interaction between MyoD and p57 Kip2 Is Competed by the Cyclin D1-Cdk4 Complexes but Not by Cyclin D1 or Cdk4
Alone-The experiments described above suggest that MyoD could bind either to cyclin D1 or Cdk4 binding sites and/or both, which are located in the NH 2 domain of p57 Kip2 . To test this hypothesis, we exploited an in vitro association/competition assay. Kip2 -covered beads were first incubated with 35 S-labeled in vitro translated MyoD (Fig. 7, lanes 6 -15) and after binding, increasing amounts of labeled cyclin D1 (Fig. 7,  lanes 7-9) , Cdk4 (Fig. 7, lanes 13-15) or cotranslated cyclin D1-Cdk4 complexes were added to the binding reactions (Fig. 7,  lanes 10 -12) and the resulting mixtures were subjected to a B, 600 g of total proteins were immunoprecipitated using affinity-purified MyoD antibodies and immune complexes were subjected to immunoblotting using anti-HA monoclonal antibodies. C, lysates (500 g) from C2C12 myoblasts (lanes 1 and 3) and C2C12 myotubes (lanes 2 and 4) were immunoprecipitated with p16
Ink4a antibodies (lanes 1 and 2) or anti-p57
Kip2 antibodies (lanes 3 and 4) . The immunoprecipitates were subjected to Western blotting with MyoD antibodies (lanes 1-4) , stripped, and reprobed with anti-p16
Ink4a (lanes 1 and 2) and anti-p57
Kip2 antibodies (lanes 3 and 4) .
GST pull-down assay. Neither increasing amounts of cyclin D1 nor Cdk4 alone affected the level of MyoD bound to p57 Kip2 , strongly suggesting that MyoD binds to p57
Kip2 independently of Cdk4 and/or cyclin D1 (Fig. 7, lanes 7-9 and lanes 13-15) . Surprisingly, when increasing amounts of cyclin D1-Cdk4 complexes were added to the mixture, MyoD-p57 Kip2 complexes were dissociated (Fig. 7, lanes 10 -12) . These results suggest that MyoD does not directly interact to the cyclin-Cdk binding sites but probably with a particular conformation in the NH 2 domain of p57 Kip2 . 
FIG. 4. A, MyoD specifically bind to p57
Kip2 in vitro. Expression vectors encoding MyoD, E12, and cyclin D1 were in vitro translated by programmed reticulocyte lysates and 2 l of the products were analyzed by SDS-PAGE (lanes 1-3) . Equimolar amounts of labeled proteins were incubated with beads covered with GST (lanes 4 -6) or GST-p57
Kip2 (lanes 7-9). Binding assays were carried out in stringency condition with 150 mM NaCl and 0.5% Nonidet P40 in binding buffer. Bound proteins were analyzed by SDS-PAGE and autofluorography. As a control for specific binding in the GST pull-down assay, cyclin D1 was used. B, binding of p57 Kip2 but not p16 Ink4a protein to GSTMyoD. Expression vectors encoding E12, p16
Ink4a
, and p57
Kip2 were in vitro translated by programmed reticulocyte lysates, and 2 l of the products were analyzed by SDS-PAGE (lanes 1-3) . Similar amounts of labeled proteins were incubated with beads covered with GST-MyoD (ϩ) or GST alone (Ϫ). The binding assays were carried out as described in A. Bound proteins were analyzed by SDS-PAGE and autofluorography.
The Integrity of the ␣-Helix in the NH 2 Region Is Indispensable for p57 Kip2 -MyoD Association-Physical interaction between p57 Kip2 and MyoD may occur via a flexible domain outside the cyclin-Cdk binding sites in the amino terminus of the Cki. A domain covering amino acids 26 -47 of p57 Kip2 , a region located between the cyclin and the Cdk binding sites, has a considerable tendency to take an ␣-helical conformation, indicating that this domain is in a coiled conformation in the native protein. Such a coiled conformation is also observed in p21
Cip1 and p27 Kip1 proteins (55) . In an attempt to test the hypothesis that the ␣-helix (amino acids 26 -47) is required for p57
Kip2 -MyoD association, we generated a replacement of the highly conserved arginine (basic residue) at position 33 by a leucine (neutral residue) (mutant R33L) in the ␣-helix domain of the GST-p57
Kip2 fusion protein and tested its ability to associate with 35 S-labeled MyoD proteins by GST pull-down. As shown in Fig. 8A , substitution of arginine for leucine in the p57
Kip2 molecule enhances the stability of the ␣-helix by modifying the three-dimensional structure of p57
Kip2 molecules. Substitution of arginine at position 33 for a leucine dramatically reduced the binding of 35 S-labeled MyoD, while this mutant retained the ability to bind cyclin D1 or Cdk4 and/or cyclin D1-Cdk4 complexes (Fig. 8B) . These data suggest that the ␣-helix domain seems to play a major role in p57
Kip2 -MyoD interaction.
DISCUSSION
It has been recently proposed that phosphorylation of MyoD by Cdk1 and Cdk2 is required for its rapid degradation by the ubiquitin-proteasome pathway, and that phosphorylation of MyoD at serine 200 plays a crucial role in modulating its half-life and transcriptional activity during myoblast proliferation (44, 45) . These findings were corroborated by our recent results showing that, in proliferating myoblasts, overexpression of p57
Kip2 can reverse mitogen-mediated repression of MyoD functions. We showed that the NH 2 -terminal domain of p57
Kip2 stabilizes MyoD by inhibiting cyclin E-Cdk2 kinase activity in growing myoblasts (48) .
The data presented here support an additional role for p57 Kip2 , independent of its kinase inhibitory activity, in the positive regulation of MyoD activity.
Increased (45) . This increased level of MyoD is due to a highest half-life time induced by p57
Kip2 co-expression in C3H10T1/2 (Fig. 2) . In the presence of overexpressed FIG. 7 . Cdk4-cyclin D1 complex inhibits p57
Kip2 association with MyoD. MyoD was in vitro translated, and 5 l were preincubated with GST alone (lane 3) or GST-p57
Kip2 fusion protein (lanes 6 -15) for 2 h at room temperature. Cyclin D1 and Cdk4 were synthesized in reticulocyte lysates separately or together, and then 1, 3, and 6 l of extracts were added to the binding reaction and incubation was continued for another 1 h. Cyclin D1 alone (lanes 7-9), Cdk4 alone (lanes [13] [14] [15] or cyclin D1-Cdk4 translated together (lanes 10 -12) were analyzed by SDS-PAGE and autofluorography. IVT (in vitro translation) represents 2 l of individually translated MyoD, cyclin D1, and Cdk4, which were loaded in the same track (lane 2). Kip2 , the half-life of MyoD Ala200 protein is about 2 times longer than that of MyoD Ala200 alone. Recently it has been shown that degradation of MyoD in vitro and in vivo by the ubiquitin-proteasome pathway was regulated by specific DNA binding of the homo-and/or heterodimers (47) . Such a protection could be achieved also by direct interaction between p57
Kip2 and MyoD. Outside the NH 2 -terminal domain, the COOH-terminal sequence (also termed QT box) is a structural motif conserved with p27
Kip1 . QT box is likely to function in protein-protein interactions and at first sight to be the best motif for p57
Kip2 -MyoD association. We demonstrate a physical interaction between the basic domain of MyoD and the NH 2 -terminal region of p57
Kip2 which contains the cyclin and Cdk binding sites. This domain of p57
Kip2 encompassing amino acids 1-105, is necessary and sufficient for binding to MyoD (Fig.  6 ). This result is strengthened by the fact that the COOHterminal domain of p57 Kip2 is not required for cell cycle arrest in SAOS2 cells (17) nor to act positively on the transactivation of the MCK promoter by MyoD (48) . Thus, these data indicate that p57 Kip2 , without its QT box, can function to arrest cell cycle in G 1 and/or to stabilize MyoD.
Implication of the ␣-Helix Structure in p57 Kip2 -MyoD Interaction-An in vitro association/competition binding assay reveals that MyoD remains associated with p57
Kip2 even after addition of increasing amounts of cyclin D1 or Cdk4 alone, although these two ligands have higher affinity for p57 Kip2 than MyoD. However, p57
Kip2 -MyoD complexes are dissociated in the presence of increasing amounts of cyclin D1-Cdk4 complexes (Fig. 7) . Even if, probably, a portion of GST-p57
Kip2 is not fully saturated by MyoD and can associate with cyclin D1 and/or Cdk4 alone or both, altogether our data strongly suggest that MyoD does not bind to the cyclin nor the Cdk binding domain. This shift of MyoD by the cyclin D1-Cdk4 complexes supposes another model of interaction, implying a conformational change of p57 Kip2 . The crystal structure of p27 Kip1 kinase inhibitory domain indicates that the cyclin and the Cdk binding sites, which are located in an extended structure, are jointed by an amphipathic helix highly conserved among the Cip/Kip proteins (55) . This should explain how the Cip/Kip family inhibitors can physically interact with the isolated Cdk subunits. Binding to the cyclin-Cdk complex is significantly tighter, consistent with cooperative binding to the two subunits (55) . Similar results have been reported for p57 Kip2 and cyclin D1-Cdk4 complex interaction (17) . In this context, our results strongly suggest that MyoD associates with p57
Kip2 probably with a particular conformation which implicates the conserved amphipathic helix (Fig. 8, A and B) . It would thus appear that specific structural constraints and affinities, different from constraints in the association of p57
Kip2 with cyclin D1-Cdk4 complexes, govern interactions between p57
Kip2 and MyoD. The stabilization of MyoD associated with p57
Kip2 can be due to a change in the conformation of MyoD protein. Kip2 and human p21
Cip1 and p27 Kip1 . Boxed regions indicates the defined sites of binding for Cyclin and Cdk subunits conserved between the members of Cip/Kip family. The corresponding secondary structure elements is schematized above. The arrow indicates the point mutation in the ␣-helix.
Diagram showing the predicted helicity per residue for wild type peptide (wt) and the mutant (R33L) was calculated using the program AGADIR (61) . B, GST-p57 wt and GST-p57 (R33L) fusion proteins were produced in E. coli, and GST pulldown assays with increasing amounts of [ 35 S]methionine-labeled cyclin D1, Cdk4, cotranslated cyclin D1-Cdk4, or MyoD were carried out as described in Fig. 5 .
The ␣-helix domain spanning amino acids 25-45 in p21 Cip1 , a secondary structure relatively well conserved in p57
Kip2 (amino acids 26 -47) , has been shown to a potential multimerization domain (56) . We have recently evidenced that homodimerization of p57
Kip2 via its ␣-helix is a prerequisite for the inhibition of cyclin D1-Cdk4 kinase activity (57) . Such a structure is well known to create a surface that allows binding of ligand. In the case of the Ckis, it has been proposed that the helix axis is submitted to kink and disorder as its binds cyclin and then it becomes well ordered as it reaches Cdk2 (55) . The variable expression of MyoD protein in growing myoblasts (58) suggested that, if the autoregulatory loop of MyoD is involved in the maintenance of myogenic potential (53) , an additional back-up system must also be functioning to account for the fact that cells with undetectable levels of MyoD can nevertheless regain their myogenic potential as shown by using bromodeoxyuridine treatment. These fluctuations of MyoD in growing myoblasts have recently been precisely correlated to cell cycle progression in a study showing that MyoD protein peaks during G 1 and drop abruptly just before entry into the S phase (59) . This suggest that a mechanism takes place to reduce the level of MyoD protein when cells progress from G 1 into S. The concomitant increase of active MyoD protein and p57
Kip2 amounts in myoblasts during early myogenic differentiation could be linked by the second action of Cki upon MyoD stabilization. We show that the ␣-helix domain p57
Kip2 interacts with the basic domain of MyoD, allowing masking of the included potential degradation signal revealed by Abu Hatoum et al. (47) .
Taken together, our present data and the recent reports from others, strongly suggest that p57
Kip2 should have two additive and successive functions during the course of muscle differentiation. First, we demonstrate that association between MyoD and p57
Kip2 is weaker than that observed between p57 Kip2 and cyclin-Cdk complexes. These data support the conclusion that in late G 1 phase the main function of p57
Kip2 is to inhibit Cdk activities preventing the phosphorylation/degradation of MyoD and to allow to the myoblasts to exit from the cell cycle (60) . This mechanism regulates positively the turn over of MyoD in order to reach a threshold of transcriptional activity that triggers cell cycle withdrawal and myogenic differentiation. Second, we show a concomitant increase in the levels of MyoD and p57 Kip2 during early myogenesis and an increasing amount of MyoD bound to p57
Kip2 in myotubes versus proliferating myoblasts. In addition we found that the increase in half-life of the nonphosphorylatable MyoD mutant is less than that observed with MyoD wild type in the presence of p57 Kip2 . Altogether, our results strongly suggest that the protection of the basic domain in MyoD by the ␣-helix located in the NH 2 region of p57 Kip2 should be one of its major function upon MyoD (and probably myogenin and MRF4 since these two other MRFs physically interact with p57
Kip2 in vitro; data not shown) and because the G 1 -cyclin-Cdk complexes that are totally absent in myotubes raise the question of the persistence of the Ckis in fully differentiated cells.
These new data show that in the NH 2 region of p57 Kip2 , the highly conserved ␣-helix domain is implicated in protein-protein interaction that may confer a new specific regulatory mechanism by which the Cip/Kip protein family can act positively on myogenic differentiation. These new data argue for the persistence and the accumulation of the Cip/Kip proteins in arrested differentiated cells.
